Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [31] Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
    Parrondo, Ricardo D.
    Ailawadhi, Sikander
    Cerchione, Claudio
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Shin, Junghoon
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Lee, Jeong-Ok
    Suh, Cheolwon
    Kim, Jin Seok
    Lee, Yoo Jin
    Yoon, Sung-Soo
    Jo, Jae-Cheol
    Lee, Ho Sup
    Bang, Soo-Mee
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Suh, Cheolwon
    Yoon, Dok Hyun
    Kim, Jin Seok
    Lee, Yoo Jin
    Moon, Joon Ho
    Yoon, Sung-Soo
    Kim, Inho
    Jo, Jae-Cheol
    Lee, Ho Sup
    Park, Seong Kyu
    Shin, Ho-Jin
    Kim, Min Kyoung
    Mun, Yeung-Chul
    Lee, Mark Hong
    Park, Yong
    Eom, Hyeon Seok
    Kim, Hyo Jung
    Im, Sung Nam
    Kim, Sung-Hyun
    Do, Young Rok
    Lee, Won Sik
    Cho, Su-Hee
    Yi, Jun Ho
    Lee, Jae Hoon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 79 - 90
  • [33] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
  • [34] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Junghoon Shin
    Je-Jung Lee
    Kihyun Kim
    Chang-Ki Min
    Jeong-Ok Lee
    Cheolwon Suh
    Jin Seok Kim
    Yoo Jin Lee
    Sung-Soo Yoon
    Jae-Cheol Jo
    Ho Sup Lee
    Soo-Mee Bang
    International Journal of Hematology, 2019, 109 : 79 - 90
  • [35] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
    Shafei, Laila
    Bashir, Shaima
    Chan, Esther W.
    Abushanab, Dina
    Hamad, Anas
    Al-Badriyeh, Daoud
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [36] Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma
    Kamal, Mona
    Wang, Xin Shelley
    Shi, Qiuling
    Zyczynski, Teresa M.
    Davis, Catherine
    Williams, Loretta A.
    Lin, Hui-Kai
    Garcia-Gonzalez, Araceli
    Cleeland, Charles S.
    Orlowski, Robert
    SUPPORTIVE CARE IN CANCER, 2021, 29 (01) : 467 - 475
  • [37] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Igarashi, Natsue
    Chou, Takaaki
    Hirose, Takayuki
    Imai, Yousuke
    Ishiguro, Takuro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 518 - 523
  • [38] EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
    Tzogani, Kyriaki
    van Hennik, Paula
    Walsh, Ita
    De Graeff, Pieter
    Folin, Annika
    Sjoberg, Jan
    Salmonson, Tomas
    Bergh, Jonas
    Laane, Edward
    Ludwig, Heinz
    Gisselbrecht, Christian
    Pignatti, Francesco
    ONCOLOGIST, 2018, 23 (05): : 631 - 636
  • [39] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [40] Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
    Usmani, Saad Z.
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S71 - S77
12345